Ignite Creation Date:
2024-05-06 @ 7:29 PM
Last Modification Date:
2024-10-26 @ 3:07 PM
Study NCT ID:
NCT06029296
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2023-08-31
Brief Title:
Diclofenac as a KMO Inhibitor
Sponsor:
University of Maryland Baltimore
Organization:
University of Maryland Baltimore
Study Overview
Official Title:
Proof of Concept Diclofenac as a KMO Inhibitor in Individuals With Alcohol Use Disorder
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DKMOI
Brief Summary:
This mechanistic proof of concept laboratory study will test the pharmacological properties of diclofenac in individuals with AUD Participants will complete two sessions in which they will receive a single dose of diclofenac 100 mg or matched placebo in a randomized and double blind fashion The primary aim is to assess whether this dose of diclofenac vs placebo increases circulating levels of kynurenic acid This finding would provide evidence that diclofenac 100 mg inhibits the kynurenine 3-monooxygenase enzyme
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None